SECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (DGX) company, today announced a research collaboration with Mass General Brigham investigators at ...
A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream ...
SECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results